Potent and selective DYRK1A/B inhibitor (IC50
values are 22 and 68 nM respectively). Selective for DYRK1A/B over a panel of other kinases. Reduces accumulation of quiescent Panc1 pancreatic cancer cells in G0
under serum free conditions. Also induces DNA damage and apoptosis in quiescent Panc1 cells.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
Ewton et al.
Mol.Cancer Ther., 2011;10:2104
Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Anderson et al.